FDA Panel Sets Date To Review Sapien for High-Risk Cohort

The FDA’s advisory panel has proposed a review of Edward Lifesciences’ premarket approval (PMA) application for its Edwards Sapien transcatheter heart valve on June 13.
CardiovascularBusiness